Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency

Andrew Whelton, William Smith, J. David Wallin, Lawrence J. Hak, Barry McLean, Robert J. Goldstein, N. Martin Lunde, Gaurang M. Shah, Dag Kremer, Leslie Steed, William E. Miller, Rita Alloway

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Long-term treatment with oral torsemide was studied to determine its effectiveness in maintaining steady-state fluid balance in patients with chronic renal insufficiency by using a placebo-controlled, double-blind, random-off design. Patients with stable chronic renal insufficiency were initially titrated and then stabilized on torsemide. Once stabilized on torsemide, patients were randomly assigned in a double-blind fashion to continue on their titrated dose of torsemide or to receive a placebo. Of the 82 patients enrolled in the study, 68 were randomized to torsemide (n = 34) or placebo (n = 34). Patients who received the placebo showed a significantly greater (p < 0.001) mean increase in body weight (3.55 lb) than did patients who remained on torsemide (0.46 lb). Approximately two-thirds of the w eight gain observed in the placebo group occurred during the first 3 days after randomization. Patients continued to receive treatment unless they developed fluid accumulation that was considered deleterious to their clinical state as determined by the investigator. In the placebo group a greater number of patients discontinued treatment because of weight gain or fluid accumulation. The mean number of days on treatment after randomization was significantly higher (p < 0.001) for patients who received torsemide (26 days) than for patients who received the placebo (16 days). The lack of weight gain in the torsemide group was associated with a higher percentage of patients who showed no change or an improvement in peripheral edema status (79%) than in placebo patients (35%). No patient was withdrawn from the study because of hyperkalemia or hypokalemia. The adverse effects reported during the study were as anticipated for patients with chronic renal insufficiency that is often complicated by other underlying illnesses.

Original languageEnglish (US)
Pages (from-to)743-749
Number of pages7
JournalAmerican Journal of Therapeutics
Volume3
Issue number11
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

torsemide
Water-Electrolyte Balance
Body Fluids
Chronic Renal Insufficiency
Body Weight
Placebos
Therapeutics
Random Allocation
Weight Gain

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency. / Whelton, Andrew; Smith, William; Wallin, J. David; Hak, Lawrence J.; McLean, Barry; Goldstein, Robert J.; Lunde, N. Martin; Shah, Gaurang M.; Kremer, Dag; Steed, Leslie; Miller, William E.; Alloway, Rita.

In: American Journal of Therapeutics, Vol. 3, No. 11, 01.01.1996, p. 743-749.

Research output: Contribution to journalArticle

Whelton, A, Smith, W, Wallin, JD, Hak, LJ, McLean, B, Goldstein, RJ, Lunde, NM, Shah, GM, Kremer, D, Steed, L, Miller, WE & Alloway, R 1996, 'Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency', American Journal of Therapeutics, vol. 3, no. 11, pp. 743-749. https://doi.org/10.1097/00045391-199611000-00002
Whelton, Andrew ; Smith, William ; Wallin, J. David ; Hak, Lawrence J. ; McLean, Barry ; Goldstein, Robert J. ; Lunde, N. Martin ; Shah, Gaurang M. ; Kremer, Dag ; Steed, Leslie ; Miller, William E. ; Alloway, Rita. / Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency. In: American Journal of Therapeutics. 1996 ; Vol. 3, No. 11. pp. 743-749.
@article{21bef87ce8f04ed8952e905a5ac0a21a,
title = "Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency",
abstract = "Long-term treatment with oral torsemide was studied to determine its effectiveness in maintaining steady-state fluid balance in patients with chronic renal insufficiency by using a placebo-controlled, double-blind, random-off design. Patients with stable chronic renal insufficiency were initially titrated and then stabilized on torsemide. Once stabilized on torsemide, patients were randomly assigned in a double-blind fashion to continue on their titrated dose of torsemide or to receive a placebo. Of the 82 patients enrolled in the study, 68 were randomized to torsemide (n = 34) or placebo (n = 34). Patients who received the placebo showed a significantly greater (p < 0.001) mean increase in body weight (3.55 lb) than did patients who remained on torsemide (0.46 lb). Approximately two-thirds of the w eight gain observed in the placebo group occurred during the first 3 days after randomization. Patients continued to receive treatment unless they developed fluid accumulation that was considered deleterious to their clinical state as determined by the investigator. In the placebo group a greater number of patients discontinued treatment because of weight gain or fluid accumulation. The mean number of days on treatment after randomization was significantly higher (p < 0.001) for patients who received torsemide (26 days) than for patients who received the placebo (16 days). The lack of weight gain in the torsemide group was associated with a higher percentage of patients who showed no change or an improvement in peripheral edema status (79{\%}) than in placebo patients (35{\%}). No patient was withdrawn from the study because of hyperkalemia or hypokalemia. The adverse effects reported during the study were as anticipated for patients with chronic renal insufficiency that is often complicated by other underlying illnesses.",
author = "Andrew Whelton and William Smith and Wallin, {J. David} and Hak, {Lawrence J.} and Barry McLean and Goldstein, {Robert J.} and Lunde, {N. Martin} and Shah, {Gaurang M.} and Dag Kremer and Leslie Steed and Miller, {William E.} and Rita Alloway",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00045391-199611000-00002",
language = "English (US)",
volume = "3",
pages = "743--749",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency

AU - Whelton, Andrew

AU - Smith, William

AU - Wallin, J. David

AU - Hak, Lawrence J.

AU - McLean, Barry

AU - Goldstein, Robert J.

AU - Lunde, N. Martin

AU - Shah, Gaurang M.

AU - Kremer, Dag

AU - Steed, Leslie

AU - Miller, William E.

AU - Alloway, Rita

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Long-term treatment with oral torsemide was studied to determine its effectiveness in maintaining steady-state fluid balance in patients with chronic renal insufficiency by using a placebo-controlled, double-blind, random-off design. Patients with stable chronic renal insufficiency were initially titrated and then stabilized on torsemide. Once stabilized on torsemide, patients were randomly assigned in a double-blind fashion to continue on their titrated dose of torsemide or to receive a placebo. Of the 82 patients enrolled in the study, 68 were randomized to torsemide (n = 34) or placebo (n = 34). Patients who received the placebo showed a significantly greater (p < 0.001) mean increase in body weight (3.55 lb) than did patients who remained on torsemide (0.46 lb). Approximately two-thirds of the w eight gain observed in the placebo group occurred during the first 3 days after randomization. Patients continued to receive treatment unless they developed fluid accumulation that was considered deleterious to their clinical state as determined by the investigator. In the placebo group a greater number of patients discontinued treatment because of weight gain or fluid accumulation. The mean number of days on treatment after randomization was significantly higher (p < 0.001) for patients who received torsemide (26 days) than for patients who received the placebo (16 days). The lack of weight gain in the torsemide group was associated with a higher percentage of patients who showed no change or an improvement in peripheral edema status (79%) than in placebo patients (35%). No patient was withdrawn from the study because of hyperkalemia or hypokalemia. The adverse effects reported during the study were as anticipated for patients with chronic renal insufficiency that is often complicated by other underlying illnesses.

AB - Long-term treatment with oral torsemide was studied to determine its effectiveness in maintaining steady-state fluid balance in patients with chronic renal insufficiency by using a placebo-controlled, double-blind, random-off design. Patients with stable chronic renal insufficiency were initially titrated and then stabilized on torsemide. Once stabilized on torsemide, patients were randomly assigned in a double-blind fashion to continue on their titrated dose of torsemide or to receive a placebo. Of the 82 patients enrolled in the study, 68 were randomized to torsemide (n = 34) or placebo (n = 34). Patients who received the placebo showed a significantly greater (p < 0.001) mean increase in body weight (3.55 lb) than did patients who remained on torsemide (0.46 lb). Approximately two-thirds of the w eight gain observed in the placebo group occurred during the first 3 days after randomization. Patients continued to receive treatment unless they developed fluid accumulation that was considered deleterious to their clinical state as determined by the investigator. In the placebo group a greater number of patients discontinued treatment because of weight gain or fluid accumulation. The mean number of days on treatment after randomization was significantly higher (p < 0.001) for patients who received torsemide (26 days) than for patients who received the placebo (16 days). The lack of weight gain in the torsemide group was associated with a higher percentage of patients who showed no change or an improvement in peripheral edema status (79%) than in placebo patients (35%). No patient was withdrawn from the study because of hyperkalemia or hypokalemia. The adverse effects reported during the study were as anticipated for patients with chronic renal insufficiency that is often complicated by other underlying illnesses.

UR - http://www.scopus.com/inward/record.url?scp=0030425475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030425475&partnerID=8YFLogxK

U2 - 10.1097/00045391-199611000-00002

DO - 10.1097/00045391-199611000-00002

M3 - Article

AN - SCOPUS:0030425475

VL - 3

SP - 743

EP - 749

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 11

ER -